DNA analytics startup Bluebee has closed a Series A funding round of €10 million (about $11.4 million) from investors Capricorn ICT Arkiv, Korys, and Biover II. Prior backer Buysse & Partners also participated in the round.
The Dutch company specialises in genomic analysis and provide cloud-based performance solutions to researchers, labs, and diagnostic companies. According to the startup, the new funds will be used to further develop its platform.
“This funding will significantly boost our capacity to support our growth,” said Bluebee CEO Hans Cobben, adding that the startup has seen rapid growth in its customer base since 2014.
Bluebee has also appointed Annie Vereecken, founder of AML-Labo Riatol labs and head of Biover II who has invested in this round, to its board of advisors.
The Delft-based startup expects to see a growth in demand for genomics, the study and sequencing of an organism’s genome, in the coming year at an “industrial scale”.
“When genomics become more standard, clinicians and lab researchers will have less interest in delving into the nuts and bolts of the bioinformatics process, and will expect a secure service that is highly scalable and that just works,” says Hans Cobben.
“We enable virtually unlimited scaling up of sequencing capacity while respecting requirements for localised data processing and storage, which is a first in this industry.”
This post first appeared on Tech.eu.